Low dose BCG in the management of superficial transitional cell carcinoma of urinary bladder

ABSTRACT

76 patients with recurrent superficial bladder tumor were treated with low dose intravesical BCG therapy [20 mg] between July 1987 to March 1995. Low dose BCG therapy prevented recurrence of superficial bladder tumors in 78.9% at one year and 64.4% at 5 years follow up period. One patient developed distant metastasis in bone although there was no local recurrence after BCG in 3 years